(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058826 A1

(51) International Patent Classification[7]: C07D 211/98, A61K 31/4412, A61P 7/02

(21) International Application Number:
PCT/SE2004/001878

(22) International Filing Date:
15 December 2004 (15.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0303452-7 18 December 2003 (18.12.2003) SE
0401344-7 25 May 2004 (25.05.2004) SE

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BERGGREN, Kristina** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **DAVIDSSON, Öjvind** [SE/SE]; AstraZeneca R & D Mölndal, S-431-83 Mölndal (SE). **FJELLSTRÖM, Ola** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **GUSTAFSSON, David** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **HANESSIAN, Stephen** [CA/CA]; University of Montreal, Department of Chemistry, C.P. 6128, Succursale Centre-Ville, Montreal, Quebec H3C 3J7 (CA). **INGHARDT, Tord** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **NÅGÅRD, Mats** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **NILSSON, Ingmar** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölnstad (SE). **THERRRIEN, Eric** [CA/CA]; University of Montreal, Dep of Chemistry, C.P 6128, Succursale Centre-Ville, Montreal, Québec H3C 1J7 (CA). **VAN OTTERLA, Willem** [ZA/ZA]; University of the Witwatersrand, School of Chemistry Private Bag 3, Po, Wits 2050 (ZA).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/058826 A1

(54) Title: NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN



(I)

(57) Abstract: There is provided a compound of formula (I) wherein R^1, R^{2a}, R^{2b}, R^{3a}, R^{3b}, R^4, R^5, R^6, A, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competetive inhibitors of trypsin-like proteases, such as trombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e,g. conditions, such as thrombo-embolisms, where inhibition of trombin is required or desired, and/or conditions wherea anticoagulant thererapy is indicated).